253 related articles for article (PubMed ID: 34236595)
1. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V; Hallas J; Linder M; Margulis AV; Suehs BT; Arana A; Phiri K; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Xu Y; Kristiansen NS; Appenteng K; de Vogel S; Seeger JD;
Drug Saf; 2021 Aug; 44(8):899-915. PubMed ID: 34236595
[TBL] [Abstract][Full Text] [Related]
2. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
3. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Phiri K; Hallas J; Linder M; Margulis A; Suehs B; Arana A; Bahmanyar S; Hoffman V; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Kristiansen NS; Appenteng K; de Vogel S; Seeger J
Curr Med Res Opin; 2021 May; 37(5):867-877. PubMed ID: 33591859
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
7. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
Katoh T; Igawa Y; Yamaguchi O; Kato D; Hamada T; Kuroishi K
Low Urin Tract Symptoms; 2020 Jan; 12(1):68-80. PubMed ID: 31571403
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.
Lozano-Ortega G; Walker DR; Johnston K; Mickle A; Harrigan S; Rogula B; Kristy RM; Hairston JC; Schermer CR
Drugs Aging; 2020 Nov; 37(11):801-816. PubMed ID: 32960422
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of an α
Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
Vonesh E; Gooch KL; Khangulov V; Schermer CR; Johnston KM; Szabo SM; Rumsfeld JS
PLoS One; 2018; 13(10):e0205640. PubMed ID: 30325968
[TBL] [Abstract][Full Text] [Related]
12. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
Khullar V; Cambronero J; Angulo JC; Wooning M; Blauwet MB; Dorrepaal C; Martin NE
BMC Urol; 2013 Sep; 13():45. PubMed ID: 24047126
[TBL] [Abstract][Full Text] [Related]
15. Long-term persistence with mirabegron in a real-world clinical setting.
Wada N; Watanabe M; Banjo H; Tsuchida M; Hori J; Tamaki G; Azumi M; Kita M; Kakizaki H
Int J Urol; 2018 May; 25(5):501-506. PubMed ID: 29651798
[TBL] [Abstract][Full Text] [Related]
16. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.
Kato D; Uno S; Van Schyndle J; Fan A; Kimura T
Int J Urol; 2017 Oct; 24(10):757-764. PubMed ID: 28833621
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study.
Margulis AV; Hallas J; Pottegård A; Kristiansen NS; Atsma WJ; Franks B; D'Silva M; Varas-Lorenzo C; Perez-Gutthann S; Arana A
Eur J Clin Pharmacol; 2018 Feb; 74(2):193-199. PubMed ID: 29134254
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
